share_log

NLS Pharmaceutics Receives Notice Of Allowance For U.S. Patent Titled 'MAZINDOL TREATMENT FOR HEROIN DEPENDENCE AND SUBSTANCE USE DISORDER'

Benzinga Real-time News ·  Dec 1, 2022 01:01

$NLS Pharmaceutics (NLSP.US)$ Receives Notice Of Allowance For U.S. Patent Titled 'MAZINDOL TREATMENT FOR HEROIN DEPENDENCE AND SUBSTANCE USE DISORDER'

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment